Cecilia Jones Sells 2,542 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agios Pharmaceuticals Trading Down 4.4 %

Shares of AGIO opened at $42.47 on Wednesday. Agios Pharmaceuticals, Inc. has a twelve month low of $19.80 and a twelve month high of $53.28. The firm has a market capitalization of $2.41 billion, a P/E ratio of -6.72 and a beta of 0.75. The stock’s fifty day simple moving average is $45.47 and its 200 day simple moving average is $40.01.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.51) earnings per share. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently modified their holdings of the business. Farallon Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after acquiring an additional 63,900 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Agios Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock valued at $162,926,000 after acquiring an additional 44,583 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Agios Pharmaceuticals by 6.0% during the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock valued at $78,479,000 after acquiring an additional 200,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after acquiring an additional 388,381 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in shares of Agios Pharmaceuticals by 2.4% during the fourth quarter. First Trust Advisors LP now owns 1,818,643 shares of the biopharmaceutical company’s stock valued at $40,501,000 after acquiring an additional 43,476 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on AGIO shares. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $60.00 to $56.00 in a report on Friday, September 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $52.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.